Abstract 457P
Background
Vitamin D deficiency is associated with various kinds of cancer. Moreover, vitamin D level possibly has an inverse relationship with cancer mortality. The data on vitamin D status among Thai cancer patients and its association with cancer survival are scarce. Objectives: The primary outcome was to determine the prevalence of vitamin D deficiency among unselected Thai cancer patients. The secondary outcomes were to explore the effect of cancer treatment upon vitamin D status, the independent predictive factor(s) of vitamin D deficiency among cancer patients and its potential independent factor of cancer survival.
Methods
There were 106 consecutive cancer patients participated in this prospective descriptive study conducted at Division of Medical Oncology. Vitamin D (25(OH) D) levels were collected before and after cancer treatment. Demographic data, vitamin D status, and treatment outcomes were collected and analysed.
Results
There were 106 consecutive cancer patients participated in this study. Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators found that almost all of the cancer patients had vitamin D deficiency (102 of 106, 96.2%). Determination of vitamin D status after cancer treatment were obtained in 76 patients. The investigators did not demonstrate the significant change of vitamin D level (mean change = -1.46 (95% C.I., -3.33-0.41), p = 0.124) when the blood samples were collected before and after cancer treatment. Therefore, cancer treatment was unlikely to affect the vitamin D status. There was a trend towards inverse relationship between the BMI and vitamin D level. At the median follow-up time of 254.5 days (IQR 220-297), the investigators revealed that low BSA (BSA < 1.5 m2), PS 2 at presentation was the independent predictive factors of survival, according to the multi-variate analysis.
Conclusions
Nearly all Thai cancer patients have vitamin D deficiency. Cancer treatment does not affect the vitamin D status. Low serum vitamin D level does not affect survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chavapon Ngokngarm/Vajira hospital, Thailand.
Funding
Medical Research Fund of Faculty Medicine Vajira Hospital, Navamindradhiraj University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract